Trial Evaluating Hypo-fractionated Accelerated Versus Conventional Fractionated Adjuvant RT in Head & Neck Malignancies

Hypo-fractionated radiotherapy reduces the OTT (overall treatment time) which may in turn reduce rapid accelerated repopulation of clonogenic cells during waiting period after surgery. If this holds true, there is a potential to achieve better loco-regional control in with PORT for HNSCC. There is a strong radiobiological and economic rationale for delivery hypo-fractionated radiotherapy in HNSCC. The HYPCON III trial will be aimed to reduce the number of fractions by 50% (30 fr to 15 fr)

NCT Number	NCT07573956
Lead Sponsor	All India Institute of Medical Sciences Collaborators: Indian Council of Medical Research
Conditions	Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)
Enrollment	369 participants
Start Date	2026-02-10
Primary Completion	2028-06-30 (estimated)
Study Completion	2028-12-30 (estimated)
Updated on ClinicalTrials.gov	2026-05-07